Skip to content

Perception of the COVID-19 Pandemic in Patients With Haematological or Solid Neoplasias

Investigation of the Perception of the COVID-19 Pandemic in Patients With Haematological or Solid Neoplasias Using Patient-reported Outcome Measures (PROMs)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04649320
Enrollment
300
Registered
2020-12-02
Start date
2020-11-23
Completion date
2020-12-31
Last updated
2020-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

SARS-CoV-2, COVID19 pandemic, cancer patients, distress, HRQOL

Brief summary

Cancer patients are among the most vulnerable individuals, whose health-related quality of life (HRQOL) may be substantially impacted by the COVID19 pandemic. We want to study how the COVID-19 pandemic influences the life of cancer patients and how these patients cope with the additional distress with the aim to facilitate the development of improved future interventional strategies to maintain resilience and HRQOL

Detailed description

In December 2019, the novel human pathogenic virus SARS-CoV2 from the coronavirus family was identified, causing a respiratory disease known as COVID19 (coronavirus disease 2019). COVID19 manifests itself primarily with influenza-like symptoms, but in special cases it can lead to severe conditions such as ARDS (acute respiratory distress syndrome). Compared to other pulmotropic viruses such as the influenza virus, SARS-CoV-2 is associated with a higher contagiousness and mortality. Haematological and oncological patients are particularly vulnerable due to their advanced age, immunological restrictions in the context of the underlying disease and the treatment modalities (chemotherapy, radiation therapy, ...). To evaluate the effects of the COVID19 pandemic on the perception of patients with malignant diseases, we aim to record so-called patient-reported outcomes (PROs) from patients at the University Hospital of Innsbruck at the Department of Internal Medicine V (Hematology and Oncology) and at the Department for Radiotherapy and Radiation Oncology. We use the validated EORT QLQ-C30 and a specially developed questionnaire for COVID19.

Interventions

OTHERquestionnaire

1. 13-item questionnaire about cancer patient's distress and everyday life, 2. EORTC-QLQ-C30

Sponsors

Medical University Innsbruck
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 years * validated hematological or oncological disease * informed consent

Exclusion criteria

* Age \< 18 years * Insufficient discernment

Design outcomes

Primary

MeasureTime frameDescription
Influence of the COVID-19 pandemic on cancer patient's daily lifesingle timeevaluation via questionnaire

Countries

Austria

Contacts

Primary ContactReinhard Stauder, M.D.
reinhard.stauder@i-med.ac.at+43 512 504 81387

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026